Abstract 1127: Bcr-Abl inhibition in leukemia cells creates metabolic addictions
Abstract Bcr-Abl kinase inhibitors are the standard therapy for chronic myelogenous leukemia (CML). While effective in controlling disease in chronic phase, these inhibitors often fail to completely eliminate Bcr-Abl+ CML cells and also fail to achieve durable remissions for advanced CML and Bcr-Abl...
Saved in:
Published in | Cancer research (Chicago, Ill.) Vol. 72; no. 8_Supplement; p. 1127 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
15.04.2012
|
Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!